Trial Type: Lung Cancer

S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC

A Phase 1 Study of NM32-2668 (Anti ROR1/Anti CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors

LS-P-Poppy: First-in-class antibody-drug conjugate (ADC) targeting fibronectin (PYX-201) for solid tumors

ADC targeting EGFR and cMET (AZD9592) for metastatic colorectal cancer and EGFR mutated lung cancers that have progressed after standard therapy

Pan RAS/MAPK inhibitor for solid tumors. Cohorts in lung cancer with KRAS/BRAF mutations and other mutations in this pathway

JDQ443 for first-line treatment for KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

Neoadjuvant ipilimumab and nivolumab with low dose SBRT fir resectable stage IB=III NSCLC. Closed to accrual. Open to biospecimen donation.

Bifunctional antibody against EGFR and TGF Beta, alone and in combination with pembrolizumab for Head and neck cancer, NSCLC and anal cancer and cutaneous squamous cell cancer

inhibitor of MTAP for patients with MTAP gene alterations in gastric esophageal, NSCLC and bladder cancer

Phase I/II study of DF1001 Trinket immunotherapy for HER2 expressing tumors: Open cohorts are for breast cancer, colon cancer and NSCLC